Purchase this article with an account.
Haoyu Chen, Xulong Liao, Chuang Jin, Weiqi Chen, Guihua Zhang, Lingping Cen, Siu Chun Danny Ng; Quantification of Anterior Chamber Reaction after Intravitreal Injections of Conbercept and Ranibizumab: a pilot study. Invest. Ophthalmol. Vis. Sci. 2019;60(9):122.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
Inflammation is an important adverse reaction after intravitreal injection of anti-vascular endothelial growth factor (VEGF) agents. The purpose of this study is to investigate the incidence and risk factors of anterior chamber reaction after intravitreal injections of anti-VEGF agents using swept-source anterior-segment optical coherence tomography (AS-OCT).
This is a prospective case series. Patients received intravitreal injections of anti-VEGF agents were recruited. AS-OCT was used to detect aqueous cells at two time-points, before injection and 1 day after injection. Positive reaction was defined as increased more than 1 cell compared to baseline. Clinical parameters were compared between the groups with positive and negative anterior chamber reaction.
A total of 128 eyes were included. There were 39 (30.5%) cases with positive anterior chamber reaction. There was no significant difference between positive and negative groups in gender, number of injections and types of drugs injected. Patients who received Conbercept had higher incidence of positive anterior chamber reaction compared to those who received Ranibizumab (44.7% vs. 24.5%, p=0.02, Odds ratio= 2.502, 95% confidence interval: 1.124-5.569).
Significant proportion of cases developed the anterior chamber reaction after intravitreal injections of anti-VEGF agents. Conbercept had higher incidence of anterior chamber reaction than Ranibizumab.
This abstract was presented at the 2019 ARVO Annual Meeting, held in Vancouver, Canada, April 28 - May 2, 2019.
This PDF is available to Subscribers Only